SBIR/STTR Research Award
DEVELOPMENT OF MEMBRANE ANCHORED CYTOKINES AS NOVEL VACCINE ADJUVANTS FOR THE ELDERLY
Award amount
$230,270Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- METACLIPSE THERAPEUTICS CORP
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- MU6JZBDZR8X1
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
The contractor will use engineered versions of IL and GM CSF as adjuvants The engineered version of IL and GM CSF include a glycosyl phosphatidylinositol GPI anchor at the carboxyl terminal which permits their incorporation into lipid bilayers such as influenza viral like particles VLP The development of the adjuvant will be in the context of influenza in elderly populations The specific tasks include the in vitro and in vivo establishment of an immunological profile of activity to evaluate the capability of the adjuvant
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR CONCEPT AWARD FOR DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS
- Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
- DEVELOPMENT OF MEMBRANE ANCHORED CYTOKINES AS NOVEL VACCINE ADJUVANTS FOR THE ELDERLY.
- Development of Membrane Anchored Cytokines as Novel Vaccine Adjuvants for the Elderly
- IND enabling studies for a personalized immunotherapy for triple negative breast cancer
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
7 SBIR/STTR records share this UEI (2013–2025). Reported award amounts total $8,832,234. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Health and Human Services